Navigation Links
AMDL ELISA DR-70(R) (FDP) is Promising as Effective Cancer Detection Test
Date:7/14/2008

TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc., (Amex: ADL) a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced that the AMDL-ELISA DR- 70(R) (FDP) test has been shown to be a useful test for the detection of cancer in clinical practice according to an independent study of 185 patients from the Medical Department II at the University Hospital in Frankfurt Germany. The results were published in the international medical research publication Alimentary Pharmacology & Therapeutics.

The purpose of this independent study was to evaluate the potential of the DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, gallbladder, gastric, liver, pancreatic and intestinal cancers. Additionally, the quantitative value of DR-70 (FDP) was tested as a parameter for the progression of these cancers. Serum samples were taken from a total of 80 cancer patients with histologically proven malignant tumors and 100 healthy blood donors in this study. Patients with colorectal cancer were also tested for carcinoembryogenic antigen (CEA), a competing diagnostic test to AMDL-ELISA DR-70 (FDP). The complete article about AMDL-ELISA DR-70 (FDP) can be accessed via AMDL's corporate website located at http://www.amdl.com under the RESOURCES link.

"When we compared the DR-70 immunoassay with conventional tumor markers, DR-70 turned out to be superior to CEA in the detection of patients with colorectal cancer," according to the conclusion of authors. The authors also concluded that DR-70 (FDP) levels were shown to be significantly higher across all types of gastrointestinal cancers tested and not limited to specific tumor types, suggesting the AMDL-ELISA DR-70 (FDP) test could be clinically used as a global cancer detection tool.

According to the results:

-- The AMDL-ELISA DR-70 (FDP) test showed strong clinical performance

with a sensitivity of 91% and a specificity of 93% in testing

conducted on patients with hepatocellular, cholangiocellular,

pancreatic, colorectal, stomach and oesophagus cancers.

-- The test reliably differs between patients with cancer of the

gastrointestinal tract or the hepatobilary system and healthy

patients; therefore showing promise as a useful cancer detection tool

in clinical practice.

-- The study also found an association between the quantitative DR-70

value and the stage of the cancer in patients tested which suggests

the AMDL-ELISA DR-70 (FDP) test can also be used as a prognostic

factor in cancer monitoring.

About AMDL: Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs approximately 320 people in the U.S. and China. The AMDL ELISA DR-70 (FDP) cancer diagnostic test was cleared to market by the US FDA on July 13, 2008 and the Company has 4 additional pharmaceutical and diagnostic products under review by various regulatory authorities. For additional information on AMDL and its products visit the company's website at http://www.amdl.com or call +1 (714)505-4460.

AMDL Contact:

Kristine Szarkowitz

Director-Investor Relations

kszarkowitz@amdl.com

(M) (206) 310-5323

(O) (206) 201-3286


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
2. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
3. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
6. Promising Data ATIR Studies Presented by NIH Investigators
7. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
8. Follow-up Phone Surveys: Effective Customer Service Assessment Tool for Improving Satisfaction
9. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
10. Mega-Brand Success: Effective Market Strategy and Tactics
11. New VeriEye SDK from Neurotechnology Enables Development of Reliable, Cost-effective Biometric Iris Recognition Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Biocom, the association representing the Southern ... San Diego companies to ... Medicine Advocacy Fly-In. Biocom Fly-In participants had the opportunity to ... the Centers for Medicare and Medicaid Services (CMS), the National ... Representatives Susan Davis and Scott Peters ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Georgia World Congress Center in Atlanta, Georgia, will include 848 exhibitors (count as ... companies will be displaying products and services used by the scientific community in ...
(Date:2/12/2016)... , Feb. 12, 2016  BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... and Technology (AGBT) Meeting. --> ... genomic research by providing cost effective NGS library preparation ... a high-throughput, fully integrated, next generation sequencing (NGS) library ...
(Date:2/12/2016)... PLAINFIELD, N.J. , Feb. 12, 2016 /PRNewswire/ ... announced the second annual STRIVE (Strategies to Realize ... Duchenne muscular dystrophy (DMD). STRIVE provides funds to ... programs that will make meaningful contributions to the ... or fostering development of future patient advocates. ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
Breaking Biology News(10 mins):